维持与推广青霉素过敏去标签:服务提供与患者安全挑战的叙述性综述
该叙述性综述评估了在分层风险评估后直接口服青霉素激发去标签的新证据与趋势,指出超过90%的青霉素过敏标签经全面检测后不准确,不准确标签妨碍抗菌药物管理并可致患者伤害。现有研究聚焦直接去标签策略的可行性及临床与经济结局,但缺乏患者与医护人员观点及安全实施前提的证据。
要点
- 超过90%的青霉素过敏标签经全面检测后不准确。
- 不准确标签妨碍抗菌药物管理并可能造成患者伤害。
- 直接口服青霉素激发去标签需先进行分层风险评估。
核心结论
- 直接口服青霉素激发去标签策略是新兴趋势,但需分层风险评估后实施。
- 现有证据聚焦可行性与临床经济结局,患者及医护人员参与证据不足。
研究设计与样本
- 叙述性综述,评估新兴证据基础与趋势,识别实施关键组件并提出建议。
主要发现
- 超过90%的青霉素过敏标签经全面检测后不准确。
- 研究集中于直接去标签策略的可行性与临床及财务结局。
- 缺乏探索患者与医护人员观点及参与的研究。
- 安全实施、维持与推广该服务的先决条件证据存在缺口。
临床怎么用
- 对青霉素过敏标签患者行分层风险评估后考虑直接口服青霉素激发去标签。
- 实施去标签服务需关注患者与医护人员参与及安全实施前提。
局限性
- 缺乏患者与医护人员观点及参与的研究证据。
- 安全实施、维持与推广服务的先决条件证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many patients report allergies to penicillin, although in over 90% of these the label of penicillin allergy is shown to be incorrect following comprehensive testing. Inappropriate and inaccurate penicillin allergy labelling is a barrier to antimicrobial stewardship and can lead to patient harm. This review assesses an emergent evidence base and trend favouring delabelling using direct oral penicillin challenges following a stratified risk assessment of the likelihood and existence of true penicillin allergy, to identify and make recommendations for key components for implementation in standard practice. Research to date has focussed on the feasibility and clinical and financial outcomes of these direct delabelling strategies. There is a paucity of studies exploring the views and engagement of patients and healthcare professionals, and a gap in the evidence for prerequisites to safely deliver, sustain and spread the implementation of such services across health systems.
引用
- Jani YH, Williams I, Krishna MT, et al. Sustaining and spreading penicillin allergy delabelling: A narrative review of the challenges for service delivery and patient safety. Br J Clin Pharmacol. 2020. PMID: 31823385. doi:10.1111/bcp.14190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。